Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Patient Resources
COVID-19 Patient Resource Center
Clinical Trials
Search Clinical Trials
Patient Notification System
What is Clinical Research?
Volunteering for a Clinical Trial
Understanding Informed Consent
Useful Resources
FDA Approved Drugs
Professional Resources
Research Center Profiles
Clinical Trial Listings
Market Research
FDA Approved Drugs
Training Guides
Books
Events
Newsletters
JobWatch
White Papers
Patient Education
SOPs
eCFR and Guidances
White Papers
Trial Listings
Advertise
COVID-19
iConnect
Sign In
Create Account
Sign Out
My Account
Home
» Pipeline
Pipeline
April 9, 2018
Company
Drug/Device
Medical Condition
Status
Wize Pharma, Inc.
LO2A
moderate to severe Conjunctivochalasis (CCH)
Phase II trials initiated enrolling 62 subjects
Synlogic
SYNB1020
hyperammonemia in patients with cirrhosis
Phase Ib/IIa trials initiated
Amylyx Pharmaceuticals, Inc.
AMX0035
Amyotrophic lateral sclerosis (ALS)
Phase II open-label extension initiated enrolling 132 patients in the U.S.
Rigel Pharmaceuticals
fostamatinib
IgA nephropathy (IgAN)
Phase II topline results announced evaluating subjects in the U.S., Asia and Europe
Kazia Therapeutics Limited
GDC-0084
glioblastoma multiforme (GBM)
Phase II trials initiated
Eli Lilly and Company
Cyramza (ramucirumab)
hepatocellular carcinoma (HCC)
Phase III positive topline results announced evaluating 292 patients across 20 countries in North America, Asia, Europe and Latin America
Allergan, Inc.
and
Gedeon Richter Ltd.
cariprazine
bipolar I depression
Phase III positive topline results announced evaluating 493 subjects
GenSight Biologics
GS010 (rAAV2/2-ND4)
Leber Hereditary Optic Neuropathy (LHON)
Phase III topline results announced evaluating 37 subjects
Wize Pharma, Inc.
LO2A
dry-eye syndrome (DES) in patients with Sjögren's syndrome
Phase IV trials initiated enrolling 60 subjects
TARIS Biomedical
TAR-200 (GemRIS)
organ-confined or locally-advanced Muscle Invasive Bladder Cancer
Fast Track Designation granted
Tetra Discovery Partners
BPN14770
Fragile X Syndrome
Orphan Drug Designation granted
PharmAbcine Inc.
TTAC-0001
Glioblastoma Multiforme (GBM)
Orphan Drug Designation granted
Scholar Rock
SRK-015
spinal muscular atrophy (SMA)
Orphan Drug Designation granted
AstraZeneca
moxetumomab pasudotox
hairy cell leukemia (HCL)
Priority Review granted
Dr. Reddy’s Laboratories Ltd.
DFN-02
migraine
NDA filed with the FDA
AstraZeneca Pharmaceuticals LP
BYDUREON
type 2 diabetes with inadequate glycemic control
FDA approval granted
Amgen
Blincyto (blinatumomab)
B-cell precursor acute lymphoblastic leukemia (ALL)
FDA approval granted
Upcoming Events
01
Dec
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
02
Dec
Clinical Trial Risk Management in the Post-COVID-19, All-Digital World: Predictive Transformation in Quality, Compliance and Risk Management
02
Dec
2020 in Review: Celebrating the Successes of the Clinical Research Community After A Difficult Year
10
Dec
Medical Device Clinical Trials in China: Latest Regulatory Developments
Featured Products
Regenerative Medicine: Steps to Accelerate Development
Clinical Trial Agreements: A Guide to Key Words and Phrases
Featured Stories
Simple Changes Can Make Trials More Patient Friendly
Two-Thirds of Trial Subjects for Drug Approvals Are Outside the U.S.
Rules of Vaccine Approval May Be Changing, But Statistical Analysis Tools Remain Constant
Ask the Experts: Trial Operations Adjustments in a Remote World
New!
2019 Site Survey Reports
Learn More Here
